

April 27, 2023

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai: 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai: 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

In Compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended March 31, 2023.

Request you to kindly take the same on record.

Thanking you

Yours faithfully,

**For Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary & Compliance Officer**

**Encl: as above**

Glenmark Life Sciences Limited - Disclosure of Related Party Transactions for the half year ended 31st March 2023

(Amounts in Rs. Millions)

Sr. No.	Details of the party entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transactions	Value of the related party transaction as approved by the audit committee (Refer Note 5)	Remark on approval by Audit Committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
											Opening balance	Closing balance	In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity								Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Inc., USA		Fellow Subsidiary	Sale of goods or services		500.00	-	230.95	219.80	451.73								
2	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Inc., USA		Fellow Subsidiary	Any other transaction	Expenses Reimbursed	-	-	40.40	0.00	0.00								
3	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Holding Company	Purchase of goods or services		10,250.00	-	83.74	0.00	0.00								
4	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Holding Company	Sale of goods or services		10,250.00	-	3909.15	2543.83	3518.04								
5	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Holding Company	Dividend paid		-	-	2131.60	0.00	0.00								
6	Glenmark Life Sciences Limited		Viso Farmaceutica S.L.U.		Fellow Subsidiary	Purchase of goods or services		35.00	-	7.46	-8.11	-2.67								
7	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Europe Ltd., U.K.		Fellow Subsidiary	Purchase of goods or services		40.00	-	1.21	-3.13	-5.64								
8	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Europe Ltd., U.K.		Fellow Subsidiary	Any other transaction	Expenses Reimbursed	-	-	0.90	0.00	0.00								
9	Glenmark Life Sciences Limited		Glenmark Farmaceutica Ltda., Brazil		Fellow Subsidiary	Purchase of goods or services		80.00	-	35.30	-24.37	-3.30								
10	Glenmark Life Sciences Limited		Glenmark Foundation		Enterprises over which significant influence exercised by key management personnel/directors	Any other transaction	Expenditure incurred for CSR activities	70.00	-	15.50	0.00	0.00								
11	Glenmark Life Sciences Limited		Piramal Pharma Limited		Enterprises over which significant influence exercised by key management personnel/directors	Sale of goods or services		70.00	-	47.48	0.00	0.00								
12	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Holding Company	Any other transaction	Expenses Reimbursed	-	-	7.02	0.00	0.00								
13	Glenmark Life Sciences Limited		Dr. Yasir Rawjee		Managing Director & CEO	Remuneration		-	-	32.19	0.00	0.00								
14	Glenmark Life Sciences Limited		Mr. Tushar Mistry		Chief Financial Officer	Remuneration		-	-	9.58	0.00	0.00								
15	Glenmark Life Sciences Limited		Mr. Sumantra Mitra#		Executive Director	Remuneration		-	-	1.57	0.00	0.00								
16	Glenmark Life Sciences Limited		Mr. Rudolf Corriea		Company Secretary & Compliance Officer	Remuneration		-	-	1.12	0.00	0.00								
17	Glenmark Life Sciences Limited		Mr. Vinod Naik##		Executive Director	Remuneration		-	-	12.88	0.00	0.00								
18	Glenmark Life Sciences Limited		Mr. Bhavesh Pujara###		Chief Financial Officer	Remuneration		-	-	1.50	0.00	0.00								
19	Glenmark Life Sciences Limited		Mrs. Manju Agarwal		Non-executive Director	Any other transaction	Sitting Fees	-	-	0.60	0.00	0.00								
20	Glenmark Life Sciences Limited		Mr. T L Easwar		Non-executive Director	Any other transaction	Sitting Fees	-	-	0.50	0.00	0.00								
21	Glenmark Life Sciences Limited		Ms. Gita Nayyar		Non-executive Director	Any other transaction	Sitting Fees	-	-	0.70	0.00	0.00								
22	Glenmark Life Sciences Limited		Mr. Sridhar Gorthi		Non-executive Director	Any other transaction	Sitting Fees	-	-	1.00	0.00	0.00								

# Ceased to be whole time Director with effect from October 21, 2022

## Appointed as a whole time Director w.e.f. October 21, 2022

### Ceased to be a CFO with effect from April 22, 2022

Notes:

- Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.
- Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.
- Balances have been aggregated entity wise for all type of transactions and shown as net receivable/payable)
- RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- The value of the related party transaction denotes the amount approved by the Audit Committee for financial year 2022-23 except for Glenmark Pharmaceuticals Limited where the same was approved by the Audit Committee, Board of Directors, Shareholders of the Company for period October 22 to September 2023.